OncoRat: Building a Better Trap for Cancer
With high failure rates during clinical testing, oncology drug developers can benefit from multiple preclinical models. The SRG OncoRat model is aimed at setting an entirely new standard for translational research, delivering ~80-100% engraftment in a favorable rat model where tumors grow faster, more efficiently, and larger. Download the White Paper summarizing the recent Clinical Cancer Research paper featuring the OncoRat!
Reliable, Robust, Efficient.
SRG OncoRat , developed using Hera Biolabs’ technology, is a SCID rat on the Sprague-Dawley background that harbors a double knockout for the Rag2 and Il2rgamma genes. Similar to NSG mice, OncoRat demonstrates enhanced immunodeficiency, lacking B-cells, T-cells, and NK-cells. Combining these genetic changes in this immunodeficient rat allows the use of fewer animals through enhanced engraftment rates and improved tumor growth profiles for both cell-line tumor models and patient-derived xenografts (PDXs) (Figure 1). Given the many advantages of using SCID rats, OncoRat is an ideal model for combining efficacy, pharmacokinetic (PK), biomarker, and toxicology-related endpoints.